Related Experiment Video
Updated: Mar 5, 2026

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
Published on: January 20, 2023
Liposomal Formulations in Clinical Use: An Updated Review
Upendra Bulbake1, Sindhu Doppalapudi2, Nagavendra Kommineni3
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India. upendra.bulbake@gmail.com.
Abstract:
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Bioavailability
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Overview

